Tag: PF-06928316
Pfizer RSVpreF vaccine candidate gets another FDA breakthrough therapy status
Pfizer said that PF-06928316 (RSVpreF), its respiratory syncytial virus (RSV) vaccine candidate, has been granted breakthrough therapy designation from the US Food and Drug Administration ... Read More